RxDoctor Payments Data

Oscar Escobar

Pittsburgh, PANPI 1164495404

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,358 of the $2,144 with a category attached, or 63.3%. 7 manufacturers reported payments, led by Pfizer at 59.7% of the total. Reporting peaked in 2019 at $1,055 and has fallen 88.6% since, to $121 in 2025.

$2,144in general payments, 2019–2025

Across 14 payments — averaging $153.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$362
  • Biomarin Pharmaceutical Inc.$202
  • Tolmar, Inc.$176
  • Ultragenyx Pharmaceutical Inc.$86
  • Chiesi USA, Inc.$21
  • plus $17 from 1 others
$357,042in research payments, 2019–2025

Across 559 payments — averaging $638.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$141K
  • Novo Nordisk AS$121K
  • OPKO Pharmaceuticals, LLC$85K
  • Novo Nordisk$10K

What the payments were for

  • Travel & lodging$74735%
  • Food & beverage$1,35863%
  • Education$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →